Abstract: The present invention relates to a recombinant plasmid, methods and compositions for the expression of recombinant proteins with minimal N-terminal initiator methionine. The present invention also provides strategies for efficient removal of N-terminal initiator methionine in recombinant proteins expressed at industrial scale and provides method for producing proteins with minimal N-terminal initiator methionine.

Abstract: The present disclosure relates to protein-drug conjugates. The present disclosure specifically relates to the protein-drug conjugates, wherein the protein is a lectin protein having amino acid sequence of SEQ ID NO: 1; or lectin protein having at least 70% sequence identity to SEQ ID NO: 1. The disclosure further relates to process and composition of protein-drug conjugates and method of use thereof.

Abstract: The present invention relates to the protein for treatment of infectious disease caused by Coronaviridae. In particular, the invention relates to a recombinant Sclerotium rolfsii lectin for use in the treatment, reduction in progression and curing of SARS-COV2 disease in a subject in need thereof. Pharmaceutical compositions comprising said recombinant Sclerotium rolfsii lectin are also described. The recombinant Sclerotium rolfsii lectin protein may comprise an amino acid sequence having at least 70% homology to SEQ ID NO: 1.

Abstract: The present disclosure provides a modified protein sequence i.e., recombinantly expressed glycan binding protein. The said glycan binding protein is a variant of Sclerotium Rolfsii Lectin and is modified to include attributes like enhanced molecule stability, reduced N-terminal methionine impurities and aid in conjugation of protein to other biological and chemical agent(s).

Abstract: The present invention relates to recombinant proteins, compositions and methods of stabilization thereof. The invention specifically relates to the stable recombinant protein of SEQ ID NO: 1 and composition comprising recombinant protein of SEQ ID NO: 1. The invention further relates to method of preparing, storing and stabilizing recombinant protein of SEQ ID NO: 1 and its composition for longer shelf life.

Abstract: The present invention provides for a nucleic acid encoding an isomerase and uses of the isomerase for bioconversion of sugar substrates. The invention represents an advancement in the field of enzyme engineering and discloses a modified nucleic acid for achieving optimum expression of a protein having isomerase activity in a heterologous host. The invention also discloses vectors carrying the modified nucleic acid and recombinant host cells carrying the vectors. The invention also discloses the process for producing a recombinant host cell, process for production of the recombinant enzyme and the process for bioconversion of sugars into their respective isomers using the recombinant protein.

Abstract: The present invention provides for a nucleic acid encoding an isomerase and uses of the isomerase for bioconversion of sugar substrates. The invention represents an advancement in the field of enzyme engineering and discloses a modified nucleic acid for achieving optimum expression of a protein having isomerase activity in a heterologous host. The invention also discloses vectors carrying the modified nucleic acid and recombinant host cells carrying the vectors. The invention also discloses the process for producing a recombinant host cell, process for production of the recombinant enzyme and the process for bioconversion of sugars into their respective isomers using the recombinant protein.

Abstract: The present invention provides a process for preparing non-cariogenic, sustained energy release juice. The process comprises contacting juice with an enzyme immobilized on Duolite at 30-50° C. for 1-5 h; wherein the enzyme is capable of converting cariogenic sugar to non-cariogenic sugar; and separating juice from the enzyme complex.

Abstract: The present invention is directed towards genetic modification of native gene encoding for sucrose isomerase and isomaltulose synthase to substantially increase the expression level of these enzymes and use of said enzymes in a process to produce rare disaccharides such as isomaltulose and trehalulose. Also disclosed in the present invention is expression constructs comprising the modified genes and a host cells to express the same.

Abstract: The present invention is directed towards genetic modification of native gene encoding for sucrose isomerase and isomaltulose synthase to substantially increase the expression level of these enzymes and use of said enzymes in a process to produce rare disaccharides such as isomaltulose and trehalulose. Also disclosed in the present invention is expression constructs comprising the modified genes and a host cells to express the same.

Abstract: The present invention is directed towards genetic modification of native gene encoding for D-tagatose 3-epimerase and rhamnose isomerase to substantially increase the expression level of these enzymes and use of the enzymes in a process to produce rare monosaccharides such as psicose and allose. Also disclosed in the present invention is expression constructs comprising the modified genes and a host cells to express the same.

Abstract: The present invention is directed towards genetic modification of native gene encoding for sucrose isomerase and isomaltulose synthase to substantially increase the expression level of these enzymes and use of said enzymes in a process to produce rare disaccharides such as isomaltulose and trehalulose. Also disclosed in the present invention is expression constructs comprising the modified genes and a host cells to express the same.

Abstract: The present invention is directed towards genetic modification of native gene encoding for D-tagatose 3-epimerase and rhamnose isomerase to substantially increase the expression level of these enzymes and use of said enzymes in a process to produce rare monosaccharides such as psicose and allose. Also disclosed in the present invention is expression constructs comprising the modified genes and a host cells to express the same.

Abstract: The present invention is directed towards genetic modification of native gene encoding for sucrose isomerase and isomaltulose synthase to substantially increase the expression level of these enzymes and use of said enzymes in a process to produce rare disaccharides such as isomaltulose and trehalulose. Also disclosed in the present invention is expression constructs comprising the modified genes and a host cells to express the same.